Briacell Therapeutics Corp. Common Shares
BCTXBriacell Therapeutics Corp. is a biotechnology company focused on developing personalized cell therapies for cancer treatment. The company leverages its proprietary platform to design and manufacture immune cell therapies aimed at improving outcomes for patients with various cancers.
Company News
BriaCell Therapeutics Corp. announced a best-efforts offering of 1,449,300 common shares at $3.25 per share, expected to raise approximately $4.7 million in gross proceeds. The offering is scheduled to close on June 2, 2026, with net proceeds designated for working capital, general corporate purposes, and advancement of business objectives. Think...
BriaCell Therapeutics plans to consolidate its common shares at a 10:1 ratio to maintain Nasdaq listing requirements, effective August 25, 2025.
BriaCell reported promising Phase 2 survival data for Bria-IMT immunotherapy in metastatic breast cancer, showing improved median overall survival compared to Trodelvy and single-agent chemotherapy across triple-negative and hormone receptor-positive breast cancer subtypes.
The article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.
BriaCell Therapeutics Corp. announced the pricing of a $13.8 million public offering, with each unit consisting of one common share (or pre-funded warrant) and one warrant. The company plans to use the proceeds for working capital, general corporate purposes, and advancing its business objectives.
